Management Team

Eddie Gray Chief Executive Officer and Director

Mr. Gray joined Dynavax as Chief Executive Officer and was appointed to our Board in May 2013. Most recently, Mr. Gray served as the President of Pharmaceuticals Europe and a member of the corporate executive team at GlaxoSmithKline plc (GSK) since 2008 and as Senior Vice President and General Manager of Pharmaceuticals UK from 2001 through 2007. Prior to the formation of GSK, Mr. Gray was with SmithKline Beecham from 1988 through 2000 serving in various positions of increasing responsibility, including Vice President and Director of Anti-Infectives Marketing in the US, Vice President and Director of the Vaccines Business Unit in the US, and Vice President and General Manager of Pharmaceuticals in Canada. Mr. Gray received a Bachelor of Science degree in Chemistry and Management Studies from the University of London and an MBA from the Cranfield School of Management in the UK.

Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer

Robert L. Coffman, PhD, is Senior Vice President and Chief Scientific Officer of Dynavax Technologies Corporation in Berkeley, CA. Prior to joining Dynavax in 2000, Dr. Coffman was a founding member of the DNAX Research Institute in Palo Alto, CA. Dr. Coffman has authored over 200 scientific publications, is a member of the National Academy of Sciences and the American Academy of Microbiology, and has received a number of prestigious awards for his work. With colleague Dr. Tim Mosmann, he defined the two principal subtypes of helper T cells, termed Th1 and Th2 cells, and demonstrated the central relationship between their differences in cytokine expression and function. Dr .Coffman defined basic mechanisms of T-cell regulation in asthma and infectious and parasitic diseases, and demonstrated the central role of regulatory CD4+ T cells in preventing inflammatory bowel disease. At Dynavax, Dr. Coffman has pioneered the development of agonists and antagonists for Toll-like receptors, key recognition receptors in innate immunity.

Steven N. Gersten Vice President and General Counsel

Steven N. Gersten joined Dynavax in 2015 as Vice President, General Counsel, and Chief Ethics and Compliance Officer. Prior to joining Dynavax, he served as global Vice President and Ethics and Compliance Officer at AbbVie, where he helped build the compliance program and organization. From 2002 to 2013, he was employed by Abbott Laboratories, where he served as Vice President and Chief Regulatory and Compliance Counsel, and Vice President and Chief Counsel / General Counsel to several business units, setting global legal strategies and functional plans as well as overseeing the internal legal organization and external counsel. Prior to joining Abbott, Mr. Gersten held various positions of increasing responsibility with the U.S. Department of Justice (where he brought enforcement cases on behalf of the FDA), the law firms Howrey and Simon, and Shea and Gould, and with the U.S. Attorney’s Office in Washington, D.C. Mr. Gersten holds a JD degree from the Boston University School of Law and a BS degree from Boston University School of Management.

Robert Janssen Chief Medical Officer and Senior Vice President, Clinical Development

Dr. Janssen was appointed Chief Medical Officer and Vice President, Clinical Development in July 2013. He most recently served as Dynavax's Vice President, Medical Affairs since November 2012 and was previously Senior Director, Clinical Development at Dynavax from 2010 through 2012, during which time he was extensively involved with Phase 3 clinical development of HEPLISAV-B and its US and European licensing applications. Prior to joining Dynavax, Dr. Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of physician and health care provider education focused on HIV and hepatitis B therapies. Until 2008, Dr. Janssen spent 23 years at the US Centers for Disease Control and Prevention (CDC), most recently as the Director of the Division of HIV/AIDS Prevention from 2000 to 2008. Under his leadership, CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of pre-exposure prophylaxis for HIV. Dr. Janssen received a Bachelor of Arts degree with Honors in Humanities from Stanford University and his M.D. degree from the University of Southern California. He is a neurologist with training in virology at the University of Pennsylvania. Dr. Janssen has been the beneficiary of numerous honors and awards during his career. He has published over 130 scientific articles in a variety of journals and has served as a reviewer for leading scientific journals.

David Novack Senior Vice President, Operations and Quality

Mr. Novack joined Dynavax in March 2013 as Senior Vice President, Operations and Quality. Mr. Novack was formerly with Novartis Vaccines & Diagnostics where he served since 2009 as the Global Head of Technical Operations and Supply Chain for Diagnostics and previously from 2007 to 2009 as the Global Head of Vaccine Manufacturing Strategy. Prior to Novartis, Mr. Novack was the Vice President, Business Development for Vaxin, Inc., a vaccine company. From 1993 until 2004, Mr. Novack worked at MedImmune, serving in several capacities including business development, manufacturing, contract operations and supply chain operations. Mr. Novack received a B.S. in Biology from State University of New York and an M.B.A. from Columbia University.

Michael S. Ostrach Senior Vice President, Chief Financial Officer and Chief Business Officer

Mr. Ostrach joined Dynavax in 2006 as Vice President, Chief Business Officer and General Counsel and became Principal Financial Officer in 2013 and Chief Financial Officer in 2015. From 2005 to 2006, he was Chief Operating Officer, Chief Financial Officer and General Counsel at Threshold Pharmaceuticals. From 1997 to 2004, Mr. Ostrach was at Kosan Biosciences, most recently as President and Chief Operating Officer. Mr. Ostrach began his corporate career at Cetus Corporation, where he served in several capacities between 1981 and 1991, initially as general counsel and finally as Senior Vice President of corporate affairs and General Counsel. Following the acquisition of Cetus by Chiron Corporation in 1991, Mr. Ostrach became President of Chiron Technologies. He holds a B.A. from Brown University and a J.D. from Stanford Law School.

Cecilia Vitug Vice President, Human Resources

Ms. Vitug has been our Vice President of Human Resources since October 2006. She previously served as Senior Director of Human Resources and Director of Human Resources since joining us in June 2000. From 1997 to 2000, Ms. Vitug was employed by Collagen Aesthetics, Inc., where she was Director of Human Resources, Payroll and Administrative Services. Ms. Vitug brings to Dynavax more than 20 years of human resources and administrative services experience, including positions at Somatix Therapy Corporation, Chiron Corporation, and Wells Fargo Bank.